Author of

• 14661

  +

  P2.08 - Poster Session/ Thymoma, Mesothelioma and Other Thoracic Malignancies (ID 225)

  • Event: WCLC 2015
  • Type: Poster
  • Track: Thymoma, Mesothelioma and Other Thoracic Malignancies
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/08/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)

  • 14681

    +

    P2.08-020 - Percutaneous Cryoablation for Pulmonary Metastasis of Soft Tissue and Bone Sarcomas (ID 352)

    09:30 - 09:30  |  Author(s): H. Asamura
    • Abstract

    Background:
    The treatment of pulmonary metastases of soft-tissue and bone sarcomas is challenging, as they are highly resistant to both chemotherapy and radiotherapy. Hence, while surgery is the treatment of choice, the treatment options are currently very limited for non-surgical patients. Therefore, the purpose of this study was to evaluate the safety and efficacy of percutaneous computed tomography (CT)-guided cryoablation for pulmonary metastases of soft tissue and bone sarcomas.
    
    Methods:
    Hospital records of patients who underwent cryoablation for metastatic lung tumors of soft-tissue and bone sarcomas were reviewed. Percutaneous cryoablation was performed using the Cryocare system (Endocare, Irvine, CA) and multi-slice CT fluoroscopy. CT scans were obtained immediately after the procedure; follow-up CT was performed on days 1, 7, 30, and 90, and subsequently at 6-month intervals. The procedural safety, local progression-free survival, and overall survival were assessed retrospectively.
    
    Results:
    Between 2002 and 2011, percutaneous cryoablation was performed on 20 patients (12 men and 8 women; median age, 46 years; age range, 17-83 years) for 56 metastatic lung tumors of soft tissue and bone sarcomas, during a total of 36 sessions. Of the 20 patients, 2 (10%) refused surgery and 18 (90%) were considered inoperable due to multiple tumors or insufficient pulmonary function. Of the 36 sessions, pneumothorax occurred in 12 (33%), transient hemoptysis in 11 (31%), and hemothorax in 1 session (3%). Of the 12 sessions with pneumothorax, 1 (8%) required chest tube insertion. No surgical intervention was required for any of these complications. With a median follow-up of 27 months, 2 tumors (4%) showed disease progression at the original cryoablation site. The local progression-free survival rates at 1 and 3 years after cryoablation were 95% each, and the 1- and 3- year overall survival rates were 77% and 49%, respectively. Four patients were alive over 5 years after cryoablation.
    
    Conclusion:
    Percutaneous cryoablation is a feasible and efficient treatment option for inoperable metastatic lung tumors of soft tissue and bone sarcomas.